Osteoarthrosis

3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
ReCap, Hip resurfacing system, BiometPhase 41 trial
Active Trials
NCT00116948CompletedEst. Jan 2012
IBSA Institut Biochimique
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
1 program
1
Chondroitin 4&6 sulfatePhase 31 trial
Active Trials
NCT00291499CompletedEst. Aug 2010
UP
UCB PharmaBelgium - Brussels
1 program
1
10 mg of Hydrocodone Bitartrate Extended ReleasePhase 21 trial
Active Trials
NCT02222740Completed37Est. Dec 2002

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.ReCap, Hip resurfacing system, Biomet
IBSA Institut BiochimiqueChondroitin 4&6 sulfate
UCB Pharma10 mg of Hydrocodone Bitartrate Extended Release

Clinical Trials (3)

Total enrollment: 37 patients across 3 trials

NCT00116948Merck & Co.ReCap, Hip resurfacing system, Biomet

A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter

Start: Jan 2005Est. completion: Jan 2012
Phase 4Completed

Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand

Start: Jun 2005Est. completion: Aug 2010
Phase 3Completed
NCT02222740UCB Pharma10 mg of Hydrocodone Bitartrate Extended Release

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

Start: Sep 2002Est. completion: Dec 200237 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space